How Samsung Biologics drives future growth to meet evolving market demand
The contract development and manufacturing organization (CDMO) market continues to evolve as biologics pipelines expand and development programs become more complex. In 2026, the biopharmaceutical industry is looking beyond capacity alone, placing greater importance on partners that can consistently and reliably support diverse modalities, global supply chains, and rapidly advancing technologies.
Discussions at the recent J.P. Morgan Healthcare Conference reflected this shift. As molecule types diversify, development timelines tighten, and external uncertainty persists, expectations for CDMO partnerships are evolving. Execution, operational continuity, and supply resilience are becoming central measures of long-term collaboration.
Targeted investments to support manufacturing readiness and supply resilience
Rather than pursuing expansion for scale alone, CDMOs across the industry are becoming more deliberate in how and where they invest. Capital allocation is increasingly focused on strengthening existing operations, improving readiness, and ensuring that facilities are prepared to support a wider range of programs across development and commercial manufacturing.
Within this environment, Samsung Biologics continues to prioritize long-term manufacturing readiness through targeted investments. Updates shared at the conference highlighted steady capacity ramp-up alongside efforts toward geographical diversification for supply resilience. Planned investments in antibody-drug conjugates (ADCs) and small-scale manufacturing further reflect a targeted approach to addressing evolving client needs while maintaining operational continuity.
Digital advancement for enhanced operational consistency
As operating environments grow more complex, technology is playing a greater role in consistent delivery. Automation and digital systems are enhancing visibility, traceability, and coordination across multi-site manufacturing networks. While artificial intelligence continues to develop, practical applications that strengthen data integration and process understanding are gaining traction.
Samsung Biologics is fortifying its digital systems across manufacturing and quality operations with these objectives in mind. As programs scale, initiatives spanning digital twin technology, predictive analytics, and real-time data monitoring are supporting stable operations, clearer decision-making, and supply continuity.
Together, these efforts reflect a broader industry recognition that digitalization can help reduce operational variability and support reliable execution amid growing complexity.
Broadening support for diverse modalities
As therapies continue to evolve, strategic partnerships with CDMOs are becoming increasingly vital. While monoclonal antibodies (mAbs) remain the foundation of biologic therapies, accounting for a significant share of existing pipelines and commercial products, the demand continues to rise for next-generation modalities like antibody-drug conjugates (ADCs), multispecific antibodies, and cell and gene therapies. While these formats offer new therapeutic opportunities, they also create greater technical and operational intricacies.
“Biopharma companies are relying more on specialized CDMOs to manage the intricacies of these complex modalities,” said Hannah Chung of the Market Intelligence team. “Partnerships can drive efficiency, speed, and scalability in biologics manufacturing, empowering clients to focus on their core capabilities while outsourcing the complexities of development and production to trusted CDMOs.”
In response, Samsung Biologics continues to broaden its service portfolio to support both established antibody programs and more complex molecules. The company is planning to offer drug product (DP) services for ADCs in early 2027. As part of its long-term strategy to further support advanced therapies including vaccines or cell and gene therapies, the company has also finalized land acquisition for Bio Campus III.
Strengthening supply continuity amid a shifting global landscape
Supply continuity is another growing area of focus for biopharmaceutical companies as they navigate external uncertainties. Geopolitical factors, economic variability, and logistical challenges have made it clear that flexibility and resilience matter as much as technical capability.
Across the CDMO landscape, developing manufacturing networks and operating models that can support consistent delivery is increasingly valued, given their impact on development timelines, regulatory commitments, and ultimately patient access.
Samsung Biologics aligns with this trend. In addition to expanding manufacturing presence in the U.S., the company has enhanced supply chain resilience through investments that improve global responsiveness to clients.
Looking ahead
As the CDMO market moves into 2026 and beyond, rising expectations for execution, reliability, and operational readiness will further propel growth. Current trends in capital investments, technology adoption, and modality diversification indicate that the market is preparing for the long-term capability building over short-term expansion.
Within this dynamic landscape, Samsung Biologics continues to advance its operational capabilities across manufacturing readiness, digitalization, multi-modal support, and supply continuity. Building on its optimized manufacturing framework, ExellenS™, the company consolidates its capabilities across the product lifecycle to support consistent delivery and clients’ evolving needs.
The contract development and manufacturing organization (CDMO) market continues to evolve as biologics pipelines expand and development programs become more complex. In 2026, the biopharmaceutical industry is looking beyond capacity alone, placing greater importance on partners that can consistently and reliably support diverse modalities, global supply chains, and rapidly advancing technologies.
Discussions at the recent J.P. Morgan Healthcare Conference reflected this shift. As molecule types diversify, development timelines tighten, and external uncertainty persists, expectations for CDMO partnerships are evolving. Execution, operational continuity, and supply resilience are becoming central measures of long-term collaboration.
Targeted investments to support manufacturing readiness and supply resilience
Rather than pursuing expansion for scale alone, CDMOs across the industry are becoming more deliberate in how and where they invest. Capital allocation is increasingly focused on strengthening existing operations, improving readiness, and ensuring that facilities are prepared to support a wider range of programs across development and commercial manufacturing.
Within this environment, Samsung Biologics continues to prioritize long-term manufacturing readiness through targeted investments. Updates shared at the conference highlighted steady capacity ramp-up alongside efforts toward geographical diversification for supply resilience. Planned investments in antibody-drug conjugates (ADCs) and small-scale manufacturing further reflect a targeted approach to addressing evolving client needs while maintaining operational continuity.
Digital advancement for enhanced operational consistency
As operating environments grow more complex, technology is playing a greater role in consistent delivery. Automation and digital systems are enhancing visibility, traceability, and coordination across multi-site manufacturing networks. While artificial intelligence continues to develop, practical applications that strengthen data integration and process understanding are gaining traction.
Samsung Biologics is fortifying its digital systems across manufacturing and quality operations with these objectives in mind. As programs scale, initiatives spanning digital twin technology, predictive analytics, and real-time data monitoring are supporting stable operations, clearer decision-making, and supply continuity.
Together, these efforts reflect a broader industry recognition that digitalization can help reduce operational variability and support reliable execution amid growing complexity.
Broadening support for diverse modalities
As therapies continue to evolve, strategic partnerships with CDMOs are becoming increasingly vital. While monoclonal antibodies (mAbs) remain the foundation of biologic therapies, accounting for a significant share of existing pipelines and commercial products, the demand continues to rise for next-generation modalities like antibody-drug conjugates (ADCs), multispecific antibodies, and cell and gene therapies. While these formats offer new therapeutic opportunities, they also create greater technical and operational intricacies.
“Biopharma companies are relying more on specialized CDMOs to manage the intricacies of these complex modalities,” said Hannah Chung of the Market Intelligence team. “Partnerships can drive efficiency, speed, and scalability in biologics manufacturing, empowering clients to focus on their core capabilities while outsourcing the complexities of development and production to trusted CDMOs.”
In response, Samsung Biologics continues to broaden its service portfolio to support both established antibody programs and more complex molecules. The company is planning to offer drug product (DP) services for ADCs in early 2027. As part of its long-term strategy to further support advanced therapies including vaccines or cell and gene therapies, the company has also finalized land acquisition for Bio Campus III.
Strengthening supply continuity amid a shifting global landscape
Supply continuity is another growing area of focus for biopharmaceutical companies as they navigate external uncertainties. Geopolitical factors, economic variability, and logistical challenges have made it clear that flexibility and resilience matter as much as technical capability.
Across the CDMO landscape, developing manufacturing networks and operating models that can support consistent delivery is increasingly valued, given their impact on development timelines, regulatory commitments, and ultimately patient access.
Samsung Biologics aligns with this trend. In addition to expanding manufacturing presence in the U.S., the company has enhanced supply chain resilience through investments that improve global responsiveness to clients.
Looking ahead
As the CDMO market moves into 2026 and beyond, rising expectations for execution, reliability, and operational readiness will further propel growth. Current trends in capital investments, technology adoption, and modality diversification indicate that the market is preparing for the long-term capability building over short-term expansion.
Within this dynamic landscape, Samsung Biologics continues to advance its operational capabilities across manufacturing readiness, digitalization, multi-modal support, and supply continuity. Building on its optimized manufacturing framework, ExellenS™, the company consolidates its capabilities across the product lifecycle to support consistent delivery and clients’ evolving needs.
Share article
Related Content